Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014131 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Kidney Cancer
A Phase 1 study, sponsored by Lisata Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT00014131: Clinical Trial Phase 1 study, sponsored by Lisata Therapeutics.
NCT00014131 is a Phase 1 study that was terminated before completion, run by Lisata Therapeutics. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014131, a Phase 1 study, was terminated before completion, sponsored by Lisata Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent or stage III or stage IV kidney cancer.
Interventions
- BIOLOGICAL Biological/Vaccine: therapeutic autologous dendritic cells.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2001-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
Why NCT00014131 stopped before completion
NCT00014131 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which Biological/Vaccine: therapeutic autologous dendritic cells. is the first listed.
NCT00014131 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00014131 about?
NCT00014131 is a clinical study titled "Vaccine Therapy in Treating Patients With Kidney Cancer". RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent or stage III or stage IV kidney cancer.
What is the current status of trial NCT00014131?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2001-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00014131?
The interventions under investigation include: Biological/Vaccine: therapeutic autologous dendritic cells. (BIOLOGICAL).
Who is sponsoring clinical trial NCT00014131?
This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00014131's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia